Market revenue in 2021 | USD 3.7 billion |
Market revenue in 2030 | USD 6.0 billion |
Growth rate | 5.6% (CAGR from 2021 to 2030) |
Largest segment | Anti-hypertensive |
Fastest growing segment | Hormones |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD billion |
Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 16.22% in 2021. Horizon Databook has segmented the Mexico branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is the second-largest pharmaceutical market in Latin America followed by Brazil. The branded generics market is anticipated to witness moderately high growth over the forecast period owing to increasing investments by generic players coupled with government initiatives.
According to the National Association of Drug Manufacturers, 86% of pharmaceuticals used in the country are produced internally, which makes the country highly self-sufficient. In addition, strategic initiatives by global players further accelerate market growth.
As per a survey in 2019, around 87.2% of Mexican patients buy generic products, which is anticipated to drive market growth. Moreover, regulatory bodies in the country, such as COFEPRIS, are undertaking various strategic initiatives to increase availability generic drugs in the Mexican market, thereby reducing the out-ofpocket spending of individuals.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico branded generics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account